Endo Oxymorphone ER Response To FDA “Approvable” Letter Expected In 2005

The firm will submit a new study, designed under FDA’s special protocol assessment procedures, in 250-300 opioid-naïve patients with chronic low back pain. Bias concerns raised about dropouts in other trials will be addressed through titration.